IP Library Patent Application 16129096
Patent Application
App. No. 16/129,096

INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/129,096
Abstract

The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.

Claims (12)

1 - 23 . (canceled)

24 . A composition comprising: (a) a recombinant AAV9 (rAAV9) comprising a self-complementary genome comprising a CLN6 gene; and (b) a transduction agent.

25 . The composition of claim 24 , wherein the transduction agent is a contrast agent.

26 . The composition of claim 25 , wherein the contrast agent is a non-ionic, low-osmolar contrast agent.

27 . The composition of claim 26 , wherein the non-ionic, low-osmolar contrast agent is selected from the group consisting of iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, and combinations thereof.

28 . The composition of claim 26 , wherein the non-ionic, low-osmolar contrast agent is iohexol.

29 . A method of treating a CLN6 disease in a patient in need thereof comprising, administering to the patient by intrathecal delivery an effective amount of a composition of claim 24 .

30 . The method of claim 29 , further comprising placing the patient in the Trendelenberg position after intrathecal delivery of the composition.

31 . The method of claim 29 , wherein the transduction agent is a contrast agent.

32 . The method of claim 31 , wherein the contrast agent is a non-ionic, low-osmolar contrast agent.

33 . The method of claim 32 , wherein the non-ionic, low-osmolar contrast agent is selected from the group consisting of iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, and combinations thereof.

34 . The method of claim 32 , wherein the non-ionic, low-osmolar contrast agent is iohexol.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: PORENSKY, PAUL N.; BURGHES, ARTHUR H.M.
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 055256/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2021
From: KASPAR, BRIAN K.
To: NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 055256/0394 →